The level of biosimilar market sustainability differs between countries, largely due to variances in biosimilar policies and years of experience managing a biosimilar market.
This article originally appeared on The Center for Biosimilars®.
Although many countries have sustainable biosimilar policies to some degree, policies regarding biosimilar education and understanding need to be improved to ensure the market is sustainable long-term, according to an international study published in Frontiers in Pharmacology.
The study aimed to gain understanding about how policies can influence market success across the world and offer possible solutions to support biosimilar sustainability.
“This study proposes a set of elements that should underpin sustainable biosimilar policy development over time in a country,” wrote the authors. "At first, biosimilar policies should guarantee the safety and quality of biosimilars, healthy levels of supply and a level of cost savings. As a country gains experience with biosimilars, policies need to optimise uptake and combat any misconceptions about biosimilars."
Policies from 17 countries were assessed. The list included 3 countries from North America (Canada, Mexico, and the United States), 1 from South America (Brazil), 2 from the Asia-Pacific region (Australia and Japan), 9 from Europe (Belgium, France, Germany, Italy, the Netherlands, Norway, Spain, Switzerland, and the United Kingdom), and 2 Gulf Cooperation Council nations (Saudi Arabia and United Arab Emirates). The broad selection was to ensure that countries with different policy archetypes and different levels of economic development were represented.
Country-specific literature reviews were conducted to identify peer-reviewed articles, official government sources, and other forms of media on biosimilar policies and the results were validated by 23 international and local non-industry experts, and 2 advisory board meetings with the experts.
A framework was developed to assess policy sustainability and utilized a rating system using 5 answer categories:
The main finding was that European countries typically had higher sustainability scores than other countries. This was unsurprising because European countries tend to have more experience with biosimilars and more developed policy frameworks. For example, the European Union and the United Kingdom have about 10 years more experience with biosimilars compared with the United States.
Policies that were considered sustainable included:
However, the authors noted that improvements to policies regarding biosimilar contracting approaches as well as education and understand of biosimilars can be made in all study countries.
One of the issues that arose concerned the perception of a policy’s sustainability. The authors found that some policy areas—like those regarding contracting, prescribing, dispensing, and monitoring—were rated as “sustainable for all stakeholders” in some countries but not in others (Chart).
The authors had 4 main takeaways from the results on how countries should implement biosimilar policies:
Reference
Alnaqbi KA, Bellanger A, Brill A, et al. An international comparative analysis and roadmap to sustainable biosimilar markets. Front Pharmacol. Published online August 24, 2023. doi:10.3389/fphar.2023.1188368
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
USPSTF Lowers Age for Biennial Mammograms to 40, Citing Early Detection Benefit
April 30th 2024The USPSTF lowered the recommended starting age for mammograms from 50 to 40 years, citing moderate benefits for early detection in this age group. Disparities persist, especially for Black women, highlighting the need for improved access to health care and social support.
Read More
Makers of medical tests will have about 4 years to show the FDA that their new offerings deliver accurate results; after previously decreasing for 27 years, US tuberculosis (TB) cases increased every year since 2020; a US district judge rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to the Medicare drug price negotiation program.
Read More